“Akolat” is leucotriene receptor antagonist, new drug for basic therapy of bronchial asthma
Abstract
The open investigation of 60 mild to moderate bronchial asthma patients was caried out to test the efficacy and safety of "Akolat". Non-smoking adult males and females who received short-acting inhaled beta-agonists as monotherapy or combinated with inhaled corticosteroids in dose up to 1000 meg daily were involved in this investigation. The efficacy was evaluated according to the asthmatic symptoms score, dynamics of pulmonary function parameters and to changes in frequency of taking beta-agonists.
The significant improvement in daytime asthma symptoms evaluation (score number decreased by 56%), reduction of freqiency of nighttime awakenings because of asthma (by 53%) and reduction of mean number of mornings with asthma in a week (from 4.5 to 2.5) were registered after 6-week treatment with “Akolat” in 20 mg 2 times daily. Also the improvement of lung function (FEV1 and REF values increased accordingly by 16.8% and 22.6%) and reduction of beta-agonists necessity were noted. All the changes were statistically reliable. Side effects were basically mild to moderate and as a rule they did not require to abolish the drug. Two patients only had given up taking the drug because of unfavourable phenomens which were solved for two days.
Conclusion: “Akolat" is effective and well-tolerable drug for basic therapy of mild to moderate asthma.
About the Authors
N. A. Kolganova
НИИ пульмонологии М3 РФ
Russian Federation
Russian Federation
G. L. Osipova
НИИ пульмонологии М3 РФ
Russian Federation
Russian Federation
L. A. Goryachkina
НИИ пульмонологии М3 РФ
Russian Federation
Russian Federation
A. S. Demborinskaya
НИИ пульмонологии М3 РФ
Russian Federation
Russian Federation
E. P. Terekhova
НИИ пульмонологии М3 РФ
Russian Federation
Russian Federation
B. M. Blokhin
НИИ пульмонологии М3 РФ
Russian Federation
Russian Federation
V. V. Aldonina
НИИ пульмонологии М3 РФ
Russian Federation
Russian Federation
References
1. Intenational consensus report on the diagnosis and treatment of asthma / / Eur. Respir. J.— 1992.— Vol. 5.— P.601—642.
2. Haahtela T. et at. Effects of reducing or discontinuing inhaled budisonide in patients with mild asthma / / N. Engl. J. Med.— 1994.— Vol.331, № П .— P.700—705.
3. Shaw A., Krell R.D. Pepetide leukotrienes: current status of i research / / J. Med.Chem.— 1991.— Vol.34, № 4.— P. 1235—1242.
4. Quanjer P.H., Tammeling G.J., Cotes J.E. et at. Lung volumes and forced ventilatory flows / / Eur. Respir. J.— 1993.— Vol.6, Suppl. 16.— P.5—40.
5. American thoracic society, standardization of spirometry — 1987 update / / Am. Rev. Respir. Dis.— 1987.— Vol. 136.— P. 1285—1298.
6. Smith L.J., Geller S ., Ebright L. et at. Inhibition of leukotriene D4-induced bronchoconstriction in normal subject by the oral LTD4 receptor antagonist ICI 204,219 / / Am. Rev. Respir. Dis.— 1990,— Vol.141, № 4.— P.988—992.
7. Taylor I.K., O’Shaughnessy K.M., Fuller R.W. et al. Effect of cysteinyl-leukotriene receptor antagonist ICI 204,219 on allergeninduced bronchoconstriction and airway hyperreactivity in atopic sybjects / / Lancet.— 1991.— Vol.337.— P.690—694.
8. Weiss J.W., Drazen J.M., McFadden E.R.Jr. Airway consrtriction in normal humans produced by inhalation of leukotriene D: potency, Time course, and effect of aspirin therapy / / J. Am. Med. Assoc.— 1983.— Vol.249.— P.2814—2817.
9. Soter N.A., Lewis R.A., Corey E.J. et al. Local effects of synthetic leukotrienes (LTC4, LTD4, LTE4 and LTB4) in human skin / / J. Invest. Dermatol.— 1983.— Vol.80.— P.115—119.
10. Bernstein J.A., Greenberger P.A., Patterson R. et al. The effect of the oral leukotriene antagonist, ICI 204,219 on leukotriene D4 and histamine-induced cutaneous vascular reactions in man / / J. Allergy Clin. Immunol.— 1991.— Vol.87.— P.93—99.
11. Winzel S.E., Larson G.L., Johnston K. et al. Elevated levels of leukotriene C4 in bronchoalveolar lavage fluid from atopic asthmatics after endobronchial allergen challenge / / Am. Rev. Respir. Dis.— 1990.— Vol.142.— P.l12—119.
12. Taylor G.W., Taylor I., Black P. et al. Urinary leukotriene E4 after allergen challenge and in acute asthma and allergic rhinitis / / Lancet.— 1989.— Vol.l.— P.584—588.
Review
For citations:
Kolganova N.A., Osipova G.L., Goryachkina L.A., Demborinskaya A.S., Terekhova E.P., Blokhin B.M., Aldonina V.V. “Akolat” is leucotriene receptor antagonist, new drug for basic therapy of bronchial asthma. PULMONOLOGIYA. 1998;(3):24-28. (In Russ.)
Views:
336
Email this article 